<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Instil-Bio on 生物经济</title><link>https://cn.bioecon.ru/companies/instil-bio/</link><description>Recent content in Instil-Bio on 生物经济</description><generator>Hugo</generator><language>zh-CN</language><lastBuildDate>Sat, 11 Jul 2026 14:19:14 +0700</lastBuildDate><atom:link href="https://cn.bioecon.ru/companies/instil-bio/index.xml" rel="self" type="application/rss+xml"/><item><title>TIL 疗法（肿瘤浸润淋巴细胞）</title><link>https://cn.bioecon.ru/technology/til-therapy/</link><pubDate>Fri, 19 Jun 2026 00:00:00 +0000</pubDate><guid>https://cn.bioecon.ru/technology/til-therapy/</guid><description>TIL 疗法——具有多克隆特异性的自体肿瘤浸润 T 细胞；首个获批药物 Lifileucel（Amtagvi，Iovance，FDA 2024）是转移性黑色素瘤的突破。</description></item></channel></rss>